Heron Therapeutics updates investors on business progress as development pipeline remains the key va
Heron Therapeutics is progressing its drug portfolio, focusing on operational execution and a long-term strategy for treatments in oncology support and pain management. The company's stock valuation is closely tied to its clinical development pipeline, regulatory milestones, and commercialization success. Investors are advised to consider the balance between near-term revenue and long-term prospects as the company navigates the biopharmaceutical industry's high R&D intensity and regulatory dependencies.
HRTX - Heron Therapeutics Inc Options
This page provides a detailed financial overview of Heron Therapeutics Inc. (HRTX), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, insider and institutional ownership, and short interest data, alongside recent performance metrics over different timeframes.
Is Heron Therapeutics, Inc. (HRTX) Stock a Recovery Opportunity After Cinvanti Patent Court Ruling?
Heron Therapeutics (HRTX) faces a setback after a U.S. District Court ruled against it in Cinvanti patent litigation, leading H.C. Wainwright to lower its price target. The company plans to appeal the decision, asserting confidence in its legal arguments and intellectual property. Despite the ruling not impacting previous settlement agreements, the company is determined to defend its patents for its innovative therapies.
Heron Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard
Heron Therapeutics received a notice from Nasdaq on June 25, 2026, stating that its common shares failed to meet the minimum bid price requirement of $1.00 for 30 consecutive trading days. The company has 180 days, until December 22, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive days. Trading of HRTX shares continues on The Nasdaq Capital Market.
Heron Therapeutics (HRTX) Stock Sees Fair Value Cut After Cinvanti Patent Decision
Heron Therapeutics (HRTX) has seen its analyst fair value estimate cut from US$4.75 to US$3.00 per share following a Cinvanti patent decision that invalidated claims on two patents. This revision reflects legal risks, potential generic competition for Cinvanti (which accounts for 60% of sales), and changes to revenue growth, net profit margin, and discount rate assumptions. While H.C. Wainwright highlights appeal potential, Needham downgraded the stock to Hold due to the significant legal setback.
Heron Therapeutics Receives Nasdaq Minimum Bid Price Notification
Heron Therapeutics announced it received a notice from Nasdaq regarding its non-compliance with the minimum bid price requirement. The company has 180 calendar days, until December 23, 2024, to regain compliance, with a possible extension for another 180 days. Heron's common stock will continue to trade on the Nasdaq Global Select Market under the symbol "HRTX" during this period, and the notice does not immediately impact its listing.
Heron Therapeutics Receives Nasdaq Minimum Bid Price Notification
Heron Therapeutics received a notification from Nasdaq regarding its minimum bid price requirement. The article, published by MT Newswires, provides this brief update. Access to the full article is reserved for members.
Heron Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Forbes William P
This article provides a statement of changes in beneficial ownership of securities for Officer Forbes William P at Heron Therapeutics. The document details the modifications in his holdings.
Heron Therapeutics Inc Actuals & Estimates (NASDAQ:HRTX)
This article provides an overview of Heron Therapeutics, Inc. (NASDAQ: HRTX) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details the company's financial actuals and estimates for earnings and revenue, noting past surprises and future expectations, but states the company does not pay dividends.
Heron Therapeutics Inc Actuals & Estimates (BX:AXD2)
This article provides an overview of Heron Therapeutics Inc. (BX:AXD2) stock, including its current price, market capitalization, analyst forecasts, and historical highs and lows. It also details the company's recent financial performance, such as earnings per share and revenue, and upcoming earnings report dates.
Enterprise value to revenue forward of Heron Therapeutics, Inc. – NASDAQ:HRTX
This article provides financial data specifically regarding the enterprise value to revenue forward metric for Heron Therapeutics, Inc. (NASDAQ: HRTX). It appears to be a stub or an entry on a financial data platform from TradingView, indicating that the value for this specific period is available upon navigation.
Nasdaq warns Heron Therapeutics (NASDAQ: HRTX) on sub-$1.00 bid price
Heron Therapeutics (NASDAQ: HRTX) has received a notice from Nasdaq regarding its failure to meet the minimum $1.00 bid price requirement, as its stock traded below this level for thirty consecutive days. The company has 180 calendar days, until December 22, 2026, to regain compliance by ensuring its closing bid price reaches at least $1.00 for a minimum of ten consecutive days. Failure to comply could lead to delisting, though the company may consider options like a reverse stock split and could be eligible for an additional compliance period.
Price to sales forward of Heron Therapeutics, Inc. – NASDAQ:HRTX
This article provides financial data, specifically the "Price to sales forward" for Heron Therapeutics, Inc. (NASDAQ: HRTX). It appears to be a financial snapshot from TradingView, offering a quick look at this metric, but without further details or analysis within the provided text.
Heron Therapeutics Stock - long-term strategy under pressure after reverse split and Nasdaq warning
Heron Therapeutics (HRTX) is facing a challenging long-term repositioning strategy after undergoing a 1-for-25 reverse stock split in 2024 to meet Nasdaq's minimum bid price requirements and receiving a Nasdaq listing deficiency notice. The company, focused on pain management and oncology supportive care, must balance advancing its product portfolio with controlling cash burn and securing funding. This situation is typical for smaller biotech companies that need to finance research, trials, and commercialization efforts with often limited revenue.
Heron Therapeutics Inc (HRTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Heron Therapeutics Inc (HRTX) by business segment and region for the reported fiscal years, updated on April 6. It highlights that CINVANTI, SUSTOL, ZYNRELEF, and APONVIE are the primary revenue contributors, with CINVANTI accounting for the largest proportion. All reported revenue for Heron Therapeutics Inc. originates from the United States.
Heron Therapeutics Inc (HRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Heron Therapeutics Inc (HRTX) regarding its dividend history and stock splits. It states that the company has distributed $0.00 in dividends over the past five years and that there is no historical data available for both dividend payments and stock splits. The piece essentially confirms a lack of dividend activity and stock split events for HRTX.
Heron Therapeutics stockholders approve director slate and plan amendments at annual meeting
Heron Therapeutics (NASDAQ:HRTX) stockholders approved all six proposals at their 2026 Annual Meeting on June 11, including the election of seven directors and the ratification of their accounting firm. Key amendments to equity incentive and employee stock purchase plans were also approved, despite the company's stock trading near its 52-week low and recent financial underperformance. The company has a market cap of $74.77 million and significant debt.
Heron Therapeutics Stock - Shareholders back equity plans and tax measure at 2026 meeting
Heron Therapeutics shareholders approved all proposals at their 2026 annual meeting, including significant increases to equity and employee stock purchase plans and a tax benefits preservation plan. This approval provides management with greater flexibility in using stock-based compensation as the company works through its turnaround and commercialization priorities. The company's focus remains on operational execution, cost discipline, and portfolio concentration in acute care and oncology-supportive indications, against a backdrop of recent weak share performance and operating losses.
Heron Therapeutics (NASDAQ: HRTX) CFO exercises RSUs and withholds shares for taxes
Heron Therapeutics' EVP and CFO, Ira Duarte, engaged in routine equity compensation activity, exercising 12,500 restricted stock units on June 16, 2026. To cover tax obligations, Duarte disposed of 3,555 common shares at $0.38 per share. Following these transactions, Duarte directly holds 264,628 shares of common stock and 12,500 restricted stock units.
Heron Therapeutics Inc (HRTX) Financial Health: Profitability & Balance Sheet Analysis
Heron Therapeutics Inc (HRTX) has a current financial score of 7.51, ranking 112 out of 388 in its industry, indicating weak financial status but high operating efficiency. The company's latest quarterly revenue decreased by 10.78% year-over-year to $34.71M, and its net profit saw a significant 407.82% year-over-year decline. The article highlights various aspects of its financial health, including quality of earnings, operational efficiency, growth potential, and shareholder returns, often noting that relevant data has not been fully disclosed by the company.
Heron Therapeutics Inc (HRTX) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Heron Therapeutics Inc (HRTX), evaluating its volatility, financial risk, and investment risk. The company's risk assessment score is 4.44, ranking 80 out of 388 in the Biotechnology & Medical Research industry, with a beta of 1.62 indicating higher volatility compared to the S&P 500. The report details various metrics including VaR, maximum drawdown, daily returns, Sharpe Ratio, skewness, and liquidity.
Heron Therapeutics Inc (HRTX) Valuation: PE, PB & Fair Value Analysis
Heron Therapeutics Inc (HRTX) has a current valuation score of 8.03, ranking 178 out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio is -2.11, significantly different from its recent high and low. Data for P/B, P/S, and P/CF ratios have not been disclosed yet.
Heron Therapeutics stockholders approve director slate and plan amendments at annual meeting By Investing.com
Heron Therapeutics stockholders approved all six proposals at their 2026 Annual Meeting, including the election of seven directors and the ratification of their accounting firm. They also approved executive compensation and two plan amendments related to equity incentives and employee stock purchases. Despite these approvals, the company's stock is trading near its 52-week low, and recent financial results fell short of expectations, leading H.C. Wainwright to lower its price target.
Heron Therapeutics stockholders approve director slate and plan amendments at annual meeting
Heron Therapeutics stockholders approved all six proposals at their 2026 Annual Meeting, including the election of seven directors and the ratification of their accounting firm. They also approved amendments to equity incentive and employee stock purchase plans, as well as the adoption of a Tax Benefits Preservation Plan. This comes as the company's stock trades near its 52-week low, despite analysts suggesting undervaluation.
Heron Therapeutics (HRTX) holders approve board, equity share increases and tax plan
Heron Therapeutics stockholders approved several key proposals at their 2026 Annual Meeting on June 11, 2026. This included electing seven directors, ratifying their auditor, and approving executive compensation on an advisory basis. Shareholders also significantly increased the shares authorized under the company's equity incentive and employee stock purchase plans and ratified the adoption of a Tax Benefits Preservation Plan.
Heron Therapeutics In A Tough Spot After Cinvanti Court Loss (Rating Downgrade)
Heron Therapeutics faces a significant setback after a court ruled its Cinvanti patents invalid, jeopardizing its main revenue source. The growth of Zynrelef is insufficient to compensate for potential Cinvanti losses, while other products like Aponvie and Sustol have not met expectations. The company's stock, HRTX, is downgraded to neutral due to the low probability of a successful appeal, deteriorating growth prospects, and debt covenants.
Heron Therapeutics (HRTX) EVP converts 12,500 RSUs into common shares
Heron Therapeutics' EVP, William P. Forbes, exercised 12,500 restricted stock units (RSUs) into common shares on June 6, 2026, as part of his compensation, incurring no cash cost. Following this transaction, Forbes directly holds 221,611 common shares and 12,500 RSUs that will vest in four annual installments. This transaction, detailed in a Form 4 filing, is considered a neutral event for the company, reflecting a routine compensation conversion rather than an open-market purchase or sale.
Heron Therapeutics Appeals Ruling Invalidating CINVANTI Patents
Heron Therapeutics has announced its intention to appeal a U.S. District Court ruling that invalidated patents covering its CINVANTI drug. The company will pursue this appeal to the U.S. Court of Appeals for the Federal Circuit to protect its intellectual property amidst potential generic competition. Despite this challenge, an analyst has a "Buy" rating on HRTX stock with a $3.00 price target, though TipRanks' AI Analyst rates it "Neutral" due to financial risk and weak technical trends.
Heron Therapeutics Appeals Ruling Invalidating CINVANTI Patents
Heron Therapeutics announced it will appeal a U.S. District Court ruling that invalidated patents for its CINVANTI injectable emulsion. This decision, following a Paragraph IV dispute, could impact generic competition, though it doesn't affect existing settlement agreements. Despite a negative "Spark AI Analyst" rating due to financial risk and technical trends, the company aims to defend its intellectual property and protect its oncology supportive care franchise.
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Cuts Target Price to $2
H.C. Wainwright has reiterated its Buy rating for Heron Therapeutics (HRTX.US) but has reduced the target price for the company's stock to $2. This adjustment reflects a revised outlook from the analyst firm while maintaining a positive long-term stance on the company's prospects.
U.S. District Court Issues Decision Regarding CINVANTI® Patents
Heron Therapeutics, Inc. announced that the U.S. District Court for the District of Delaware issued a decision invalidating claims of two of its patents related to CINVANTI® (aprepitant) injectable emulsion. Despite the setback, the company stated that this decision does not affect prior settlement agreements and plans to appeal the ruling to the United States Court of Appeals for the Federal Circuit. Heron's CEO, Craig Collard, expressed disappointment but affirmed the company's commitment to vigorously defending its intellectual property rights.
CINVANTI patent claims invalidated as Heron Therapeutics (NASDAQ: HRTX) plans appeal
Heron Therapeutics announced that a U.S. District Court invalidated claims of two patents covering its CINVANTI injectable emulsion, but the ruling does not affect prior settlement agreements. The company plans to appeal the decision to the U.S. Court of Appeals for the Federal Circuit and may seek a stay of market entry to defend its intellectual property. This outcome could increase the risk of generic competition for CINVANTI in the long term, depending on the appeal's result.
Court rules CINVANTI patents invalid; Heron readies appeal
A U.S. District Court has ruled two of Heron Therapeutics' CINVANTI patents invalid in a dispute with Azurity. Heron Therapeutics (HRTX) announced its intention to appeal the decision to the U.S. Court of Appeals for the Federal Circuit, emphasizing that the ruling does not impact prior settlement agreements for CINVANTI or APONVIE. Following the news, Heron's stock (HRTX) declined significantly by 15.49%, wiping out approximately $29 million in market valuation, reflecting a negative market reaction to the added legal uncertainty.
U.S. District Court Issues Decision Regarding CINVANTI® Patents
Heron Therapeutics announced that the U.S. District Court for the District of Delaware ruled its CINVANTI® patents invalid in a dispute with Azurity Pharmaceuticals. Heron expressed disappointment with the decision and plans to appeal to the United States Court of Appeals for the Federal Circuit, emphasizing their intent to vigorously defend their intellectual property rights. The company also stated that this ruling does not affect any prior settlement agreements related to CINVANTI® or APONVIE®.
Number of shareholders of Heron Therapeutics, Inc. – NASDAQ:HRTX
This article provides the number of shareholders for Heron Therapeutics, Inc. (NASDAQ: HRTX). It appears to be a financial data page from TradingView, indicating the availability of shareholder information for the specified period.
HRTX PE Ratio & Valuation, Is HRTX Overvalued
Heron Therapeutics Inc (HRTX) is deemed undervalued, with its current forward PS ratio of 0.84 significantly lower than its five-year average. The fair price for HRTX is estimated to be between $79.94 and $83.94, compared to its current price of $0.86, indicating it is undervalued by 98.93%. Despite a P/S ratio of 0.83, which is 99.72% above the industry average, and robust revenue growth of -10.78%, other metrics like P/B ratio and FCF yield show significant deviations from historical averages.
Acute care revenue growth helps Heron (HRTX) reaffirm 2026 guidance despite Q1 sales decline
Heron Therapeutics reaffirmed its 2026 revenue guidance of $550 million to $575 million, despite reporting a 13% decline in total net product sales for Q1 2026 to $27.9 million. The company's acute care segment showed significant growth, increasing 27% year-over-year to $23.6 million, largely driven by ZYNRELEF. However, oncology sales plummeted 67% to $4.3 million due to competition.
Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright?
H.C. Wainwright analyst Brandon Folkes reduced Heron Therapeutics, Inc.'s (HRTX) price target to $4 from $6, reiterating a Buy rating, following weaker-than-expected first-quarter performance and uncertainty regarding the Zynrelef product's growth. The company reported $34.7 million in Q1 2026 net revenue, with acute care revenue up 32% year-over-year, and reaffirmed full-year 2026 revenue guidance of $173–183 million. Despite product growth, the analyst emphasized the need for better revenue conversion and commercial momentum to sustain investor interest.
Heron Therapeutics (HRTX) price target decreased by 15.38% to 3.74
The article reports that the price target for Heron Therapeutics (HRTX) has been reduced by 15.38%, bringing it down to $3.74. This adjustment reflects a significant change in the financial outlook for the company based on analyst expectations.
Heron Therapeutics (HRTX) price target decreased by 15.38% to 3.74
Heron Therapeutics (HRTX) recently experienced a price target decrease of 15.38%, bringing it down to $3.74. This adjustment could reflect updated analyst expectations regarding the company's future performance or market conditions.
Heron outlines $173M-$183M 2026 net product sales outlook as it targets return to positive adjusted EBITDA
Heron Therapeutics provided a financial outlook for 2026, projecting net product sales between $173 million and $183 million. The company aims to achieve positive adjusted EBITDA during the same period, focusing on its commercial portfolio and pipeline products.
Heron Therapeutics (HRTX) Quarterly Loss Revives Dilution Fears And Tests Profitability Narrative
Heron Therapeutics (HRTX) reported a Q1 2026 loss of US$8.1 million and a basic EPS loss of US$0.04, renewing dilution concerns despite revenue of US$34.7 million. The company's trailing twelve-month net loss stands at US$30.9 million, fueling debates between bearish investors worried about ongoing cash burn and the need for external financing, and bullish analysts who foresee significant earnings growth and a shift to profitability within three years. This quarterly performance tests the narrative of future profitability against current financial realities and modest revenue growth.
Adage Capital amendment shows 0% ownership in Heron Therapeutics (HRTX)
Adage Capital Management, along with Robert Atchinson and Phillip Gross, filed an amended Schedule 13G/A, reporting 0% beneficial ownership of Heron Therapeutics (HRTX) common stock as of March 31, 2026. The filing indicates no voting or dispositive power over any HRTX shares for the reporting persons. This is considered a routine administrative amendment, as the reported ownership is below the 5% threshold.
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $4
H.C. Wainwright has reiterated its Buy rating for Heron Therapeutics (HRTX.US) and maintained its price target of $4. This indicates the firm's continued positive outlook on the company's stock performance.
Acute-care net revenue up 32% as Heron settles CINVANTI patent case
Heron Therapeutics reported Q1 2026 net revenue of $34.7 million, a 10.8% decrease year-over-year, but reaffirmed its full-year guidance for 2026. The Acute Care franchise saw strong growth with revenue up 32%, driven by ZYNRELEF and APONVIE, while Oncology Supportive Care revenue declined. The company also announced a settlement in the CINVANTI patent litigation with Baxter Healthcare.
Heron Therapeutics Inc (HRTX) Q1 2026 Earnings Call Highlights: Resilient Growth Amidst Challenges By GuruFocus
Heron Therapeutics Inc (HRTX) reported Q1 2026 net sales of $34.7 million, with acute care revenue growing 32% year-over-year despite challenges from severe weather. While gross margin was below typical levels and adjusted EBITDA was negative, the company maintained market share in oncology and provided a positive outlook for 2026 net product sales and adjusted EBITDA. Key growth drivers include the successful IGNITE program for ZYNRELEF and the pending expansion of its sales force.
Needham Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $3
Needham has reiterated its Buy rating for Heron Therapeutics (HRTX.US), indicating continued confidence in the company. The firm has also maintained its target price for HRTX.US at $3. This suggests Needham believes the stock has potential to reach this valuation.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2026 Earnings Call Transcript
Heron Therapeutics (NASDAQ:HRTX) reported its Q1 2026 earnings, missing EPS expectations at $-0.04 against an anticipated $-0.03, partially due to severe weather in January affecting elective surgeries. Despite seasonal headwinds and temporary gross margin pressure from a secondary supplier, the company reaffirmed its 2026 guidance, expecting net product sales between $173 million and $183 million and adjusted EBITDA of $10 million to $20 million, driven by strong growth in its Acute Care portfolio and strategic sales force expansion. Key growth drivers include the IGNITE program for ZYNRELEF and the inclusion of APONVIE in new consensus guidelines for postoperative nausea and vomiting.
Heron Therapeutics (NasdaqCM:HRTX) Stock Forecast & Analyst Predictions
Heron Therapeutics is forecast to grow earnings by 58.9% and revenue by 13.9% per annum, though analysts no longer expect the company to break even in the foreseeable future, predicting a net loss of US$39.7m in 2028. Recent Q1 2026 earnings missed analyst expectations, and the company's share price has shown volatility, dropping 35% over the past year. Analysts have also reduced price targets to an average of US$4.33, indicating caution despite the potential for future upside from revised profit outlook and discount rates.
Needham Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $3
Needham has reiterated its Buy rating for Heron Therapeutics (HRTX.US) and maintained its target price at $3. This indicates a continued positive outlook on the company's stock performance from the analyst firm.
